Literature DB >> 7620710

Acute withdrawal after bremazocine and the interaction between mu- and kappa-opioid receptors in isolated gut tissues.

P Valeri1, L A Morrone, L Romanelli, M C Amico.   

Abstract

1. This study was undertaken to investigate whether, after a brief exposure of guinea-pig isolated ileum and rabbit jejunum to bremazocine, a kappa-opioid agonist also possessing antagonist activity at mu-opioid receptors, the addition of opioid antagonists produced withdrawal contractures. Our aim was to verify in these tissues the existence of an interaction between the mu- and kappa-opioid systems. 2. In guinea-pig ileum preparations previously exposed for 5 min to bremazocine at 5.7 x 10(-7) M and 5.7 x 10(-8) M, naloxone (5 x 10(-7) M) elicited no response whereas in tissues exposed to a lower bremazocine concentration (5.7 x 10(-9) M), naloxone (5 x 10(-7) M) and the selective kappa-opioid antagonist, nor-binaltorphimine (3.4 x 10(-8) M) both produced a strong contracture. 3. Bremazocine (5.7 x 10(-7) M) administered to guinea-pig isolated ileum, previously exposed for 5 min to morphine (10(-7) M), induced a withdrawal contracture. In contrast, lower bremazocine concentrations (1.4 and 7.1 x 10(-8) M) did not elicit a withdrawal contracture. 4. Naloxone (5 x 10(-7) M), added to the bath after a 5 min exposure of guinea-pig ileum to morphine (10(-7) M), elicited the characteristic withdrawal contracture. Bremazocine (1.4-7.1 x 10(-8) M) added 1 min before naloxone (5 x 10(-7) M) inhibited the naloxone withdrawal contracture in a dose-related way whereas naloxone 5 x 10(-8) M added 1 min before naloxone 5 x 10(-7) M, did not affect the withdrawal response. 5. In the rabbit jejunum, bremazocine (1.4-7.1 x 10-8 M) caused a decrease in amplitude in the spontaneous tissue activity. In tissues exposed to these bremazocine concentrations, naloxone(5 x 10-7 M) elicited a marked contracture. A similar contracture occurred when nor-binaltorphimine(3.4 x 10-8 M) was added in place of naloxone. These effects were dose-related to the bremazocine concentration. The specific K-agonist, U-50,488H (5 x 10-8 M), elicited the same effects as bremazocine.6. These findings show that stimulation of K-opioid receptors induces a state of dependence that is not prevented by blocking the pi-opioid system. The observation that low bremazocine concentrations inhibit the morphine-induced withdrawal contractures, indicates an interaction between the micro- and K-opioid system in guinea-pig isolated ileum, similar to that observed in the whole animal.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620710      PMCID: PMC1510366          DOI: 10.1111/j.1476-5381.1995.tb13334.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Opioid dependence in the guinea-pig myenteric plexus is controlled by non-tolerant and tolerant opioid receptors.

Authors:  R Schulz; E Seidl; A Herz
Journal:  Eur J Pharmacol       Date:  1985-04-16       Impact factor: 4.432

2.  Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey.

Authors:  M Hutchinson; H W Kosterlitz; F M Leslie; A A Waterfield
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

3.  Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus.

Authors:  A D Corbett; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

4.  Bremazocine induces antinociception, but prevents opioid-induced constipation and catatonia in rats and precipitates withdrawal in morphine-dependent rats.

Authors:  P Petrillo; M C Gambino; A Tavani
Journal:  Life Sci       Date:  1984-08-27       Impact factor: 5.037

5.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

6.  Morphine, but not diacetyl morphine (heroin), possess opiate antagonist activity in the mouse vas deferens.

Authors:  C F Smith
Journal:  Neuropeptides       Date:  1984-12       Impact factor: 3.286

7.  The contribution of intrinsic activity to the action of opioids in vitro.

Authors:  L Miller; J S Shaw; E M Whiting
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

8.  Comparison of abstinence syndromes following chronic administration of mu and kappa opioid agonists in the rat.

Authors:  G A Young; N Khazan
Journal:  Pharmacol Biochem Behav       Date:  1985-09       Impact factor: 3.533

9.  The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs.

Authors:  P J Brent; L A Chahl; P A Cantarell; C Kavanagh
Journal:  Eur J Pharmacol       Date:  1993-09-14       Impact factor: 4.432

10.  Withdrawal responses of guinea-pig isolated ileum following brief exposure to opiates and opioid peptides.

Authors:  L A Chahl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

View more
  6 in total

1.  Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro.

Authors:  Ashish K Rehni; Nirmal Singh
Journal:  Psychopharmacology (Berl)       Date:  2011-09-20       Impact factor: 4.530

2.  Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.

Authors:  Ashish K Rehni; Nirmal Singh; Mahesh Rachamalla; Kulbhushan Tikoo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-25       Impact factor: 3.000

3.  The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.

Authors:  Pamela R Tsuruda; Ross G Vickery; Daniel D Long; Scott R Armstrong; David T Beattie
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-04       Impact factor: 3.000

4.  In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.

Authors:  Prabhat Singh; Bhupesh Sharma; Surbhi Gupta; B M Sharma
Journal:  Psychopharmacology (Berl)       Date:  2014-07-26       Impact factor: 4.530

5.  The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.

Authors:  D T Beattie; M Cheruvu; N Mai; M O'Keefe; S Johnson-Rabidoux; C Peterson; E Kaufman; R Vickery
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-06       Impact factor: 3.000

6.  Critical interactions between opioid and cannabinoid receptors during tolerance and physical dependence development to opioids in the murine gastrointestinal tract: proof of concept.

Authors:  Agata Szymaszkiewicz; Mikołaj Świerczyński; Marcin Talar; Prabhakar Reddy Polepally; Jordan K Zjawiony; Jakub Fichna; Marta Zielińska
Journal:  Pharmacol Rep       Date:  2021-06-16       Impact factor: 3.024

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.